It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
CACNA1I, a schizophrenia risk gene, encodes a subtype of voltage-gated T-type calcium channel CaV3.3. We previously reported that a patient-derived missense de novo mutation (R1346H) of CACNA1I impaired CaV3.3 channel function. Here, we generated CaV3.3-RH knock-in animals, along with mice lacking CaV3.3, to investigate the biological impact of R1346H (RH) variation. We found that RH mutation altered cellular excitability in the thalamic reticular nucleus (TRN), where CaV3.3 is abundantly expressed. Moreover, RH mutation produced marked deficits in sleep spindle occurrence and morphology throughout non-rapid eye movement (NREM) sleep, while CaV3.3 haploinsufficiency gave rise to largely normal spindles. Therefore, mice harboring the RH mutation provide a patient derived genetic model not only to dissect the spindle biology but also to evaluate the effects of pharmacological reagents in normalizing sleep spindle deficits. Importantly, our analyses highlighted the significance of characterizing individual spindles and strengthen the inferences we can make across species over sleep spindles. In conclusion, this study established a translational link between a genetic allele and spindle deficits during NREM observed in schizophrenia patients, representing a key step toward testing the hypothesis that normalizing spindles may be beneficial for schizophrenia patients.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 Broad Institute, Stanley Center for Psychiatric Research, Cambridge, USA (GRID:grid.66859.34)
2 VA Boston Healthcare System & Harvard Medical School, Department of Psychiatry, Boston, USA (GRID:grid.410370.1) (ISNI:0000 0004 4657 1992)
3 Broad Institute, Stanley Center for Psychiatric Research, Cambridge, USA (GRID:grid.66859.34); McGovern Institute for Brain Research, MIT, Cambridge, USA (GRID:grid.116068.8) (ISNI:0000 0001 2341 2786); National Autonomous University of Mexico, Department of Neurodevelopment and Physiology, Institute of Cellular Physiology, Mexico City, Mexico (GRID:grid.9486.3) (ISNI:0000 0001 2159 0001)
4 Broad Institute, Stanley Center for Psychiatric Research, Cambridge, USA (GRID:grid.66859.34); McGovern Institute for Brain Research, MIT, Cambridge, USA (GRID:grid.116068.8) (ISNI:0000 0001 2341 2786)
5 McGovern Institute for Brain Research, MIT, Cambridge, USA (GRID:grid.116068.8) (ISNI:0000 0001 2341 2786)
6 Novartis Institutes for BioMedical Research, Cambridge, USA (GRID:grid.418424.f) (ISNI:0000 0004 0439 2056)
7 Harvard University, Wyss Institute, Cambridge, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
8 Harvard Medical School, Brigham and Women’s Hospital, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)